The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Hearing technology company Nuheara (NUH) has been awarded phase two works, worth $2 million, from U.S.-based, multinational IT company HP
  • It follows the completion of proof of concept for an earbud variant, details of which are confidential
  • The extension includes a purchase order for works associated with the development and engineering of the buds
  • Nuheara partnered with HP in August and commenced work on accompanying software services
  • Shares opened 1.9 per cent lower at 5.2 cents

Hearing technology company Nuheara (NUH) has been awarded phase two works under a collaboration agreement with HP, worth $2 million.

It follows the completion of a proof of concept for an earbud variant under development for the U.S.-based, multinational IT company, details of which are confidential.

The phase two extension includes a purchase order for works associated with the development and engineering of the buds.

CEO Justin Miller said the multi-staged partnership is a strong vote of confidence in the company’s technological innovation.

“This next stage of the HP collaboration agreement is the result of Nuheara’s globally recognised leadership in hearables innovation,” Justin stated.

“We are looking forward to deepening this strategic OEM [original equipment manufacturer] partnership over the coming months,” he added.

Nuheara partnered with HP in August and commenced work on accompanying software services.

Shares have been trading 1.9 per cent lower at 5.2 cents at 10:45 am AEDT.

NUH by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system